GLP-1 and Intestinal Diseases
Research output: Contribution to journal › Review › Research › peer-review
Standard
GLP-1 and Intestinal Diseases. / Hunt, Jenna Elizabeth; Holst, Jens Juul; Jeppesen, Palle Bekker; Kissow, Hannelouise.
In: Biomedicines, Vol. 9, No. 4, 383, 2021.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - GLP-1 and Intestinal Diseases
AU - Hunt, Jenna Elizabeth
AU - Holst, Jens Juul
AU - Jeppesen, Palle Bekker
AU - Kissow, Hannelouise
PY - 2021
Y1 - 2021
N2 - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
AB - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
U2 - 10.3390/biomedicines9040383
DO - 10.3390/biomedicines9040383
M3 - Review
C2 - 33916501
VL - 9
JO - Biomedicines
JF - Biomedicines
SN - 2227-9059
IS - 4
M1 - 383
ER -
ID: 259509842